Lanthionine synthetase C-like 2 (LANCL2) therapeutics have gained increasing recognition
as a novel treatment modality for a wide range of autoimmune diseases. Genetic ablation of …

Lanthionine synthetase C-like 2 (LANCL2), a novel therapeutic target for inflammatory and
autoimmune diseases and diabetes, exerts anti-inflammatory and insulin-sensitizing effects …

Background Inflammatory bowel disease (IBD) afflicts 5 million people and is increasing in
prevalence. There is an unmet clinical need for safer and effective treatments for IBD. The …

Background Inflammatory bowel disease (IBD) is associated with disturbed mucosal innate
lymphoid cell (ILC) composition, which is correlated to the degree of intestinal inflammation …

Lanthionine synthetase cyclase-like receptor 2 (LANCL2) is a novel therapeutic target for
Crohn's disease (CD). BT-11 is a small molecule that binds LANCL2, is orally active, and …

Crohn's disease and ulcerative colitis are two chronic inflammatory bowel conditions.
Current approved biologic therapies are limited to blocking tumor necrosis factor alpha …

Crohn's disease and ulcerative colitis are two chronic inflammatory bowel diseases. Current
biologic therapies are limited to blocking tumor necrosis factor alpha. However, some …

Background The transport of transepithelial Cl-and HCO3-is crucial for the function of the
intestinal epithelium and maintains the acid-based homeostasis. Slc26a3 (DRA), as a key …

Inflammatory bowel disease (IBD) includes Crohn's disease and ulcerative colitis. These are
chronic disorders of the gut that have no known antigenic triggers and no known cures …

Background: Treatment of inflammatory bowel diseases (IBD) has tremendously improved
during the last 20 years; however, a substantial fraction of patients does not respond to …